Aktuellt
SENASTE
Redeye is encouraged by Isofol starting analysis of AGENT data, with top-line data some two to four months away. We judge that Isofol is now entering a critical period, leading up to the primary catalyst that could catapult arfolitixorin to the next stage of its journey. Given the previous uncertainty about how and when the company could start AGENT data analysis, we judge the share will react positively in anticipation of AGENT top-line data during the coming weeks and months.
LÄS MER
